GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONC) » Definitions » Operating Income

AONC (American Oncology Network) Operating Income : $-45 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network Operating Income?

American Oncology Network's Operating Income for the three months ended in Jun. 2024 was $-7 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was $-45 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. American Oncology Network's Operating Income for the three months ended in Jun. 2024 was $-7 Mil. American Oncology Network's Revenue for the three months ended in Jun. 2024 was $434 Mil. Therefore, American Oncology Network's Operating Margin % for the quarter that ended in Jun. 2024 was -1.69%.

American Oncology Network's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. American Oncology Network's annualized ROC % for the quarter that ended in Jun. 2024 was -16.77%. American Oncology Network's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -6.48%.


American Oncology Network Operating Income Historical Data

The historical data trend for American Oncology Network's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network Operating Income Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Operating Income
22.07 0.91 8.84 -17.92

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.35 0.21 -19.26 -18.89 -7.35

American Oncology Network Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Oncology Network  (OTCPK:AONC) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

American Oncology Network's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-29.38 * ( 1 - 9.91% )/( (136.298 + 179.287)/ 2 )
=-26.468442/157.7925
=-16.77 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=421.921 - 195.489 - ( 105.049 - max(0, 233.829 - 323.963+105.049))
=136.298

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=430.762 - 196.266 - ( 55.209 - max(0, 231.555 - 306.262+55.209))
=179.287

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

American Oncology Network's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.748/( ( (84.355 + max(-44.292, 0)) + (93.119 + max(-31.092, 0)) )/ 2 )
=-5.748/( ( 84.355 + 93.119 )/ 2 )
=-5.748/88.737
=-6.48 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(132.3 + 44.288 + 5.0290000000001) - (195.489 + 0 + 30.42)
=-44.292

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(125.421 + 54.28 + 8.25) - (196.266 + 0 + 22.777)
=-31.092

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

American Oncology Network's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-7.345/433.982
=-1.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


American Oncology Network Operating Income Related Terms

Thank you for viewing the detailed overview of American Oncology Network's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network Business Description

Traded in Other Exchanges
N/A
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.
Executives
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
David H Gould officer: Chief Financial Officer 7370 COLLEGE PARKWAY, SUITE 207, FORT MEYERS FL 33907
Erica Mallon officer: General Counsel 14543 GLOBAL PARKWAY, SUITE 110, FORT MEYERS FL 33913
Shalin Shah director 3402 W DR. MARTIN LUTHER KING JR. BLVD, TAMPA FL 33607
Vipul M Patel director 11704 SE 15TH CIRCLE, OCALA FL 34480
Todd Schonherz director, officer: Chief Executive Officer 14543 GLOBAL PARKWAY, 2ND FLOOR, FORT MEYERS FL 33913
Stephen Divers director, officer: Chief Medical Officer 133 HARMONY PARK CIRCLE, HOT SPRINGS AZ 71913
Vance Wright-browne director 22395 EDGEWATER DRIVE, PORT CHARLOTTE FL 33980
James Stith director ONE LETTERMAN DRIVE, CM200, SAN FRANCISCO CA 94129
Aea Growth Equity Fund Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Aea Growth Equity Fund (parallel) Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Ravi Yang Sarin director C/O ARES MANAGEMENT LLC, 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES CA 90067
Brian R Hoesterey 10 percent owner C/O AEA INVESTORS LP, 666 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10103
Kevin Nazemi director, officer: Chief Executive Officer 10485 NE 6TH ST, UNIT 3930, BELLEVUE WA 98004